An official website of the United States government
Home
SEER Inquiry System - Report
Produced: 11/22/2024 6:03 PM
Question 20200055
Inquiry Details
References:
COVID-19 Abstraction Guidelines. Updated August 2020
Question:
Solid Tumor Rules (2018)/Multiple primaries--Melanoma: Should a case with treatment delayed due to COVID-19 be abstracted as one or two primaries? It is uncertain if the invasive tumor would be a new tumor, or deeper extension/disease progression from the original tumor. See Discussion.
Discussion:
11/18/2019 Left 1st Digit/Thumb Biopsy: Atypical Melanocytic Proliferation consistent with Early Acral Lentiginous Melanoma in situ. Margins Positive. (Not a reportable diagnosis for 2019.)
12/5/2019 Left 1st Digit Shave Biopsies: Malignant Melanoma in situ. Margins Positive.
1/15/2020 Started Aldara (treatment plan: use for ~3 months then Mohs/excision, but due to COVID could not get resection until 7/2020).
7/29/2020 Left Thumb Excision: Residual Melanoma in situ. Margins Positive. Treatment Plan: re-excision.
8/6/2020 Left Thumb Re-Excision: Atypical Lentiginous Melanocytic Proliferation at the 12-2 margin may represent the advancing edge of melanoma in situ. (8/19/2020 Plan to treat the 12-2 margin as positive with in situ; plan for re-excision).
8/20/2020 Left Thumb Re-Excision & Left Nail Plate Excision: Malignant Acral Lentiginous Melanoma with extensive melanoma in situ. Breslow 1.3mm. Margins Positive. Nail plate & bed epithelium with hemorrhage and a mild increase in melanocyte density likely represent melanoma in situ.
9/4/2020 Left thumb partial amputation & Left axillary Sentinel Lymph Node Excision: Residual Malignant Melanoma in situ. 0/3 sentinel nodes positive.
Answer:
Abstract a single primary using the Solid Tumor Rules for melanoma. Report this melanoma as invasive (/3) as documented in the information from 8/20/2020. The treatment delay does not influence the number of primaries to be reported. Registries in SEER regions: Report the COVID-related information as directed in the COVID-19 Abstraction Guidelines, https://seer.cancer.gov/tools/covid-19/.
